Shandong Sito Bio-technology Co (300583.SZ) Stock Price

Shandong Sito Bio-technology Co., Ltd. generates revenue through three product segments. The Steroid Raw Materials segment produces steroid raw materials like androstenedione and 9-hydroxyandrostenedione using genetic engineering and microbial transformation technology. The Steroidal Finished Drug segment and Non-Steroidal Finished Drug segment are operated via its subsidiary, offering finished pharmaceutical products. The company's primary customers are pharmaceutical manufacturers requiring raw materials and finished drugs for further processing. The Steroid Raw Materials segment focuses on manufacturing key compounds such as androstenedione, hydroxyprogesterone, and 9-hydroxyandrostenedione. These materials are essential for the production of various steroid-based pharmaceuticals. The Steroidal Finished Drug segment provides ready-to-use pharmaceutical products, while the Non-Steroidal Finished Drug segment offers non-steroid alternatives, targeting different medical needs. Shandong Sito serves pharmaceutical companies that need raw materials for steroid-based drugs and finished drugs for distribution. The Steroid Raw Materials segment supplies critical inputs for steroid pharmaceutical production, while the Steroidal and Non-Steroidal Finished Drug segments cater to end-market demand for completed pharmaceutical products. The company's operations are centered around biotechnology-driven manufacturing of pharmaceutical ingredients and finished drugs.